CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 51 enrolled
Drug / intervention
MRI, Transthoracic Echocardiography, tonometry, EKGprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01044901
NCT01044901N/ACompleted
CompareCT.gov

Cardiovascular Complications of Sickle Cell Disease

University of Chicago·observational·Posted Jan 8, 2010·Updated Feb 23, 2022

In Brief

An observational study evaluating MRI, Transthoracic Echocardiography, tonometry, EKG for Sickle Cell Disease. Completed, enrolled 51 participants across 1 site.

Detailed Summary

In this research study, we are using heart imaging exams and blood testing, in order to gain an improved understanding of the pulmonary (lung) hypertension and cardiovascular (heart) complications that often occur in sickle cell patients. Information gathered from the healthy volunteers that participate in this study will be compared to information from the sickle cell patients in this study in order to help further our understanding.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 8, 2010
Enrollment StartMar 1, 2009
Primary CompletionFeb 1, 2021
TodayJul 2, 2026
Enrollment to primary: 11.9 yearsPosted 16.5 years ago

Interventions

MRI, Transthoracic Echocardiography, tonometry, EKGprocedure

Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.